Wednesday, April 8, 2009

What Do You Think About Rezonic/Zunrisa (Casopitant)?

Rezonic/Zunrisa (Casopitant) is a new drug that's being developed by GlaxoSmithKline (GSK). The indications will be for:
  • Treatment for Nausea/Vomiting -- Chemotherapy Induced
  • Nausea/Vomiting -- Postoperative
How does it compare to Merck's Emend (aprepitant), which is also an NK-1? Get familiar with the results of an ASCO 2008 abstract titled, "Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)." That's quite a title.

The conclusion is simple: A single oral dose of casopitant added to a regimen of OND/DEX provided a clinically significant reduction in the number of pts experiencing CINV events over the first 5 days after HEC. This benefit appeared to be maintained through repeat cycles. This regimen was generally well tolerated over all cycles.

1 comment:

  1. Well, it's far to early to say which of these drugs will be better and GSK is facing major regulatory hurdles and delays with the FDA: